[Heparin-induced type II thrombocytopenia in intensive care].
Koster
A
A
Institut für Anästhesie, Deutsches Herzzentrum Berlin, Bundesrepublik Deutschland. Koster@dhzb.de
Meyer
O
O
Kukucka
M
M
Mertzlufft
F
F
Kuppe
H
H
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D003422:Critical Care; D004305:Dose-Response Relationship, Drug; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D010976:Platelet Count; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D013923:Thromboembolism / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control
D000925:Anticoagulants; D006493:Heparin